Oncternal Therapeutics, Inc.

Ownership Transactions Reported by 16 Insiders

Symbol
ONCT on Nasdaq
Location
12230 El Camino Real, Suite 230, San Diego, CA

Insiders trading volume in the past year

Oncternal Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
James B. Breitmeyer Chief Executive Officer, Director $325K Feb 14, 2024
Hale David F Director $283K +$8.86K +3.23% Jun 20, 2024
Robert James Wills Director $89.6K +$77.4K +634% Jun 20, 2024
Richard G. Vincent Chief Financial Officer $73.1K Feb 14, 2024
Salim Yazji Chief Medical Officer $63.8K Feb 14, 2024
Gunnar F. Kaufmann Chief Scientific Officer $47K Jun 12, 2023
Chase C. Leavitt General Counsel/Secretary $42K Feb 14, 2024
Rajesh Krishnan Cto/Cso $21.8K Feb 14, 2024
Michael G. Carter Director Jun 20, 2024
Jinzhu Chen PhD Director Jun 16, 2022
Xin Nakanishi Director Jun 28, 2023
Rosemary Mazanet Director Jun 20, 2024
Charles Theuer Director Jun 20, 2024
William R. Larue Director Jun 20, 2024
Jill DeSimone Director Jun 20, 2024
Daniel L. Kisner Director Jun 20, 2024

Recent Insider Transactions by Companies or Individuals for Oncternal Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.